Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response

The present study confirms a polygenic contribution to MDD burden in the EMC patients. Larger GWAS with homogeneity in antidepressant treatments are needed to explore the genetic variation associated with ADR and realize the potential of PGS to contribute to specific response subtypes.